Abstract
Corticobasal degeneration (CBD) is a neurodegenerative disorder affecting movement and cognition, definitively diagnosed only at autopsy. Here, we conduct a genome-wide association study (GWAS) in CBD cases (n=152) and 3,311 controls, and 67 CBD cases and 439 controls in a replication stage. Associations with meta-analysis were 17q21 at MAPT (P=1.42 × 10-12), 8p12 at lnc-KIF13B-1, a long non-coding RNA (rs643472; P=3.41 × 10-8), and 2p22 at SOS1 (rs963731; P=1.76 × 10-7). Testing for association of CBD with top progressive supranuclear palsy (PSP) GWAS single-nucleotide polymorphisms (SNPs) identified associations at MOBP (3p22; rs1768208; P=2.07 × 10-7) and MAPT H1c (17q21; rs242557; P=7.91 × 10-6). We previously reported SNP/transcript level associations with rs8070723/MAPT, rs242557/MAPT, and rs1768208/MOBP and herein identified association with rs963731/SOS1. We identify new CBD susceptibility loci and show that CBD and PSP share a genetic risk factor other than MAPT at 3p22 MOBP (myelin-associated oligodendrocyte basic protein).
Original language | English |
---|---|
Article number | 7247 |
Number of pages | 7 |
Journal | Nature Communications |
Volume | 6 |
DOIs | |
Publication status | Published - 16 Jun 2015 |
Externally published | Yes |
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Nature Communications, Vol. 6, 7247, 16.06.2015.
Research output: Contribution to journal › Article › Research › peer-review
TY - JOUR
T1 - Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy
AU - Kouri, Naomi
AU - Ross, Owen A.
AU - Dombroski, Beth
AU - Younkin, Curtis S.
AU - Serie, Daniel J.
AU - Soto-Ortolaza, Alexandra
AU - Baker, Matthew
AU - Finch, Ni Cole A.
AU - Yoon, Hyejin
AU - Kim, Jungsu
AU - Fujioka, Shinsuke
AU - Mclean, Catriona A.
AU - Ghetti, Bernardino
AU - Spina, Salvatore
AU - Cantwell, Laura B.
AU - Farlow, Martin R.
AU - Grafman, Jordan
AU - Huey, Edward D.
AU - Ryung Han, Mi
AU - Beecher, Sherry
AU - Geller, Evan T.
AU - Kretzschmar, Hans A.
AU - Roeber, Sigrun
AU - Gearing, Marla
AU - Juncos, Jorge L.
AU - Vonsattel, Jean Paul G.
AU - Van Deerlin, Vivianna M.
AU - Grossman, Murray
AU - Hurtig, Howard I.
AU - Gross, Rachel G.
AU - Arnold, Steven E.
AU - Trojanowski, John Q.
AU - Lee, Virginia M.
AU - Wenning, Gregor K.
AU - White, Charles L.
AU - Höglinger, Günter U.
AU - Müller, Ulrich
AU - Devlin, Bernie
AU - Golbe, Lawrence I.
AU - Crook, Julia
AU - Parisi, Joseph E.
AU - Boeve, Bradley F.
AU - Josephs, Keith A.
AU - Wszolek, Zbigniew K.
AU - Uitti, Ryan J.
AU - Graff-Radford, Neill R.
AU - Litvan, Irene
AU - Younkin, Steven G.
AU - Wang, Li San
AU - Ertekin-Taner, Nilüfer
AU - Rademakers, Rosa
AU - Hakonarsen, Hakon
AU - Schellenberg, Gerard D.
AU - Dickson, Dennis W.
N1 - Funding Information: We gratefully acknowledge support of patients and their families for participating in this study, as well as the Foundation for PSP|CBD and Related Brain Diseases, and the PSP Genetics Study Group. N.K. is supported by a post-doctoral fellowship from the Karin & Sten Mortstedt CBD Solutions AB. O.A.R. is supported by NIH P50 NS072187 and R01 NS078086. D.W.D. is supported by NIH P50 NS072187, P50 AG016574, R01 AG037491, as well as State of Florida Alzheimer’s Disease Initiative and the Foundation for PSP|CBD and Related Brain Diseases. GDS is supported by NIH P01 AG017586 and grants from Foundation for PSP|CBD and Related Brain Diseases and Peebler PSP Research Foundation. N.E.-T. is supported by R01 AG032990, R01 NS080820, and P50 AG0016574. J.K. is supported by GHR Foundation. J.Q.T. is supported by NIH P30 AG10124, P01 AG17586, and P50 NS53488. B.G. is supported by NIH P30 AG10133. C.L.W. is supported by NIH P30 AG012300. G.U.H. is funded by the Deutsche For-schungsgemeinschaft (DFG: HO2402/6–2) and Bundesministerium für Bildung und Forschung (BMBF: EpiPD). L.I.G. is supported by CBD Solutions, The Rainwater Charitable Foundation. and the American Parkinson’s Disease Association. U.M. was supported by Foundation for PSP|CBD and Related Brain Diseases. I.L. is supported by MJFF, NIH, Foundation for PSP|CBD and Related Brain Diseases, and CBD Solutions. Z.K.W. is partially supported by the NIH P50 NS072187, the Mayo Clinic Center for Regenerative Medicine, Neuroscience Focused Research Team programme, and a gift from Carl Edward Bolch, Jr and Susan Bass Bolch. Funding Information: Supplementary Information accompanies this paper at http://www.nature.com/ naturecommunications Competing financial interests: Dr Trojanowski may accrue revenue in the future on patents submitted by the University of Pennsylvania wherein he is the co-inventor and he received revenue from the sale of Avid to Eli Lily as co-inventor on imaging-related patents submitted by the University of Pennsylvania. He receives research support from the NIH, GSK, Janssen and several non-profits. Publisher Copyright: © 2015 Macmillan Publishers Limited. All rights reserved.
PY - 2015/6/16
Y1 - 2015/6/16
N2 - Corticobasal degeneration (CBD) is a neurodegenerative disorder affecting movement and cognition, definitively diagnosed only at autopsy. Here, we conduct a genome-wide association study (GWAS) in CBD cases (n=152) and 3,311 controls, and 67 CBD cases and 439 controls in a replication stage. Associations with meta-analysis were 17q21 at MAPT (P=1.42 × 10-12), 8p12 at lnc-KIF13B-1, a long non-coding RNA (rs643472; P=3.41 × 10-8), and 2p22 at SOS1 (rs963731; P=1.76 × 10-7). Testing for association of CBD with top progressive supranuclear palsy (PSP) GWAS single-nucleotide polymorphisms (SNPs) identified associations at MOBP (3p22; rs1768208; P=2.07 × 10-7) and MAPT H1c (17q21; rs242557; P=7.91 × 10-6). We previously reported SNP/transcript level associations with rs8070723/MAPT, rs242557/MAPT, and rs1768208/MOBP and herein identified association with rs963731/SOS1. We identify new CBD susceptibility loci and show that CBD and PSP share a genetic risk factor other than MAPT at 3p22 MOBP (myelin-associated oligodendrocyte basic protein).
AB - Corticobasal degeneration (CBD) is a neurodegenerative disorder affecting movement and cognition, definitively diagnosed only at autopsy. Here, we conduct a genome-wide association study (GWAS) in CBD cases (n=152) and 3,311 controls, and 67 CBD cases and 439 controls in a replication stage. Associations with meta-analysis were 17q21 at MAPT (P=1.42 × 10-12), 8p12 at lnc-KIF13B-1, a long non-coding RNA (rs643472; P=3.41 × 10-8), and 2p22 at SOS1 (rs963731; P=1.76 × 10-7). Testing for association of CBD with top progressive supranuclear palsy (PSP) GWAS single-nucleotide polymorphisms (SNPs) identified associations at MOBP (3p22; rs1768208; P=2.07 × 10-7) and MAPT H1c (17q21; rs242557; P=7.91 × 10-6). We previously reported SNP/transcript level associations with rs8070723/MAPT, rs242557/MAPT, and rs1768208/MOBP and herein identified association with rs963731/SOS1. We identify new CBD susceptibility loci and show that CBD and PSP share a genetic risk factor other than MAPT at 3p22 MOBP (myelin-associated oligodendrocyte basic protein).
UR - http://www.scopus.com/inward/record.url?scp=84935832302&partnerID=8YFLogxK
U2 - 10.1038/ncomms8247
DO - 10.1038/ncomms8247
M3 - Article
C2 - 26077951
AN - SCOPUS:84935832302
SN - 2041-1723
VL - 6
JO - Nature Communications
JF - Nature Communications
M1 - 7247
ER -